Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Interest & Investment Income (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Interest & Investment Income for 6 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 27.26% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.5 million through Dec 2025, down 28.0% year-over-year, with the annual reading at $19.5 million for FY2025, 28.0% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $4.7 million at 4D Molecular Therapeutics, up from $4.3 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $7.5 million in Q2 2024, with the low at -$312000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $3.1 million, with a median of $3.2 million recorded in 2023.
  • Peak annual rise in Interest & Investment Income hit 10775.0% in 2021, while the deepest fall reached 7900.0% in 2021.
  • Over 5 years, Interest & Investment Income stood at -$312000.0 in 2021, then soared by 528.85% to $1.3 million in 2022, then soared by 227.35% to $4.4 million in 2023, then skyrocketed by 47.65% to $6.5 million in 2024, then decreased by 27.26% to $4.7 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $4.7 million, $4.3 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.